Cargando…
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
INTRODUCTION: Lurbinectedin is a selective inhibitor of oncogenic transcription U.S. Food and Drug Administration (FDA)-approved for patients with relapsed small cell lung cancer (SCLC) as monotherapy at 3.2 mg/m(2) every 3 weeks (q3wk). ATLANTIS was a phase 3 study in SCLC with lurbinectedin 2.0 mg...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311440/ https://www.ncbi.nlm.nih.gov/pubmed/37397388 http://dx.doi.org/10.3389/fonc.2023.1152371 |